Memorial Sloan Kettering Cancer Center
-
GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers
A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.
-
New study ties pharma payments to prescription practices
Recent efforts to improve transparency haven’t made much of a difference, one author noted. But earlier reforms made a dent the “most egregious” practices.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Jury awards BMS subsidiary $752M in CAR-T patent infringement suit
A federal jury in California found that Kite Pharma – now part of Gilead Sciences – violated a patent from Memorial Sloan Kettering Cancer Center and licensed to BMS’ Juno Therapeutics in developing the CAR-T therapy Yescarta, approved in 2017.
-
Resignation by Memorial Sloan Kettering’s Baselga should start bigger COI conversation, expert says
Memorial Sloan Kettering Chief Medical Officer Jose Baselga resigned Thursday following publication of a New York Times-ProPublica investigation of his financial relationships with drugmakers.
-
Report: Top oncologist failed to disclose industry financial relationships
Memorial Sloan Kettering’s Dr. Jose Baselga, a top breast cancer doctor, omitted relationships from journal articles, including more than $3 million in payments from Roche, The New York Times and ProPublica reported.
-
Researchers develop ‘armored’ CAR-T with potential against solid tumors
Mouse model study uses PD-1 antibody technology from Eureka Therapeutics, which is also developing T-cell receptor therapies.
-
Memorial Sloan Kettering and Cota want to use data to advance cancer treatment
The two New York City-based organizations have partnered on an initiative aimed at precision oncology research and treatment. By leveraging Cota’s classification system, Memorial Sloan Kettering will improve patient care and accelerate research efforts.
-
Memorial Sloan Kettering and Philips want to upgrade precision oncology
As part of a new research collaboration, Memorial Sloan Kettering Cancer Center and Philips will be using DNA sequencing technologies to better understand pancreatic cancer.
-
ASCO: MRIs, contrast-enhanced mammography useful for small breast tumors
“There is a real need to detect cancers that are small [less than 1 cm] before they metastasize. That would be the Holy Grail.”
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Drug pricing debates: Can we quantify what a life’s worth?
Industry and academia could be drifting when it comes to evaluating appropriate drug pricing. Here are two views – from venture capitalist Dr. John LaMattina and oncologist Dr. Peter Bach.
-
At ASCO15 meeting: Breakthrough melanoma treatment, Memorial Sloan Kettering oncologist slams cancer drug price tags (Morning Read)
Bristol-Myers Squibb revealed results of Phase 3 study of combined melanoma treatment that could be a cancer treatment breakthrough, but comes with a big price tag and side effects.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
